BioPharma Dive April 19, 2021
IQVIA

Facts and figures. Let’s start with some to frame why real world data (RWD) and the real world evidence (RWE) it delivers continue to grow in significance. RWD and RWE bring increasing value to pharmaceutical and medical technology (MedTech) companies to accelerate study timelines, shorten time to market, demonstrate safety and efficacy, and even maximize commercial success.

  • In a published report based on a 2020 industry survey, more than 80% of responding companies indicated they are entering into strategic partnerships to access new sources of RWD.1
  • Almost all companies expect to increase investments in talent, technology, and external partnerships to strengthen their RWE capabilities.2
  • 90% of respondents reported they have either already established or are currently investing in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Big Data, Biotechnology, EMR / EHR, Health IT, Medical Devices, Pharma, Pharma / Biotech, Survey / Study, Technology, Trends
Related Articles:
If data is the new oil, there’s going to be war over it
Microsoft dives into data integrity at the latest VentureBeat AI Impact Tour
How Data Engineering Helps Health Systems Reach Their Most Critical Goals
The well for AI training data is running dry. Big Tech heavyweights are taking extraordinary measures to deal with the drought.
HIMSS 2024 Advancing Healthcare with High Performance Computing (HPC) and Cybersecurity

Share This Article